NAPLEX (North American Pharmacist Licensure Examination) Practice Exam 2025 - Free NAPLEX Practice Questions and Study Guide

Question: 1 / 1820

What does Carfilzomib inhibit?

DNA replication

Angiogenesis

Proteosomes

Carfilzomib inhibits proteosomes, specifically the chymotrypsin-like activity of the 20S proteasome. This is important in cancer treatment, as it targets the breakdown of proteins, which can contribute to cancer cell growth. Neither DNA replication, angiogenesis, nor EGFR are inhibited by carfilzomib. DNA replication is a central process in cell division and is targeted by some chemotherapy drugs, but not carfilzomib. Angiogenesis is the formation of new blood vessels, which plays a role in cancer growth, but this is not directly inhibited by carfilzomib. EGFR (epidermal growth factor receptor) is a protein involved in cell signaling and is often mutated in cancer, but carfilzomib does not specifically target EGFR.

Get further explanation with Examzify DeepDiveBeta

EGFR

Next Question

Report this question

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy